Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

Pfizer408 enrolled

Overview

The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)

Study Type

OBSERVATIONAL

Enrollment

408

Conditions

Invasive Pneumococcal Disease

Interventions

Pneumococcal 7-valent conjugate vaccine PrevnarDRUG

Eligibility

Sex: ALLMax age: 5 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD. * Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.

Locations (1)

Pfizer Investigational Site

Bilbao, Spain

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.